CSR1 Antibody

What is CSR1/CSRP1 protein and what is its significance in research?

CSR1 (Cellular Stress Response 1), also referred to as CSRP1 (Cysteine and Glycine-Rich Protein 1), is a 21-23 kDa protein implicated in cellular stress response pathways. Its significance in research stems from its demonstrated role as a tumor suppressor, particularly in prostate cancer where it has been shown to dramatically reduce tumor size, invasion rate, and mortality in xenograft models . The protein is characterized by its LIM domain structure and is expressed in multiple cell types, making it relevant to both cancer research and broader studies of cellular stress response mechanisms .

How is CSRP1 expression regulated in normal versus cancerous tissues?

CSRP1 expression is frequently down-regulated in cancerous tissues compared to normal tissues. Analysis of multiple data sets has shown that CSRP1 mRNA expression is significantly reduced in prostate cancer tissues, with more dramatic reductions (up to 4.5-fold decrease) observed in cases that subsequently developed metastasis or experienced PSA relapse . Regulation occurs at both transcriptional and epigenetic levels, with methylation of the CSR1 promoter serving as a significant mechanism of expression control. Immunohistochemical studies have confirmed this pattern at the protein level, with approximately 77% of prostate cancer samples showing weak or negative CSRP1 staining .

What critical factors should be considered when selecting a CSRP1 antibody for research applications?

When selecting a CSRP1 antibody, researchers should consider:

• Cross-reactivity profile: Verify whether the antibody recognizes human, mouse, rat, or multiple species based on experimental needs. Many commercial CSRP1 antibodies (such as catalog #DF3119 and #AF5739) offer cross-reactivity across human, mouse, and rat samples .

• Application compatibility: Confirm the antibody has been validated for your specific application (Western blot, immunohistochemistry, immunofluorescence). Not all antibodies perform equally across different techniques .

• Immunogen information: Review the specific peptide or protein region used as immunogen to ensure it aligns with your research needs and to predict potential cross-reactivity with related proteins like CSRP2 or CSRP3 .

• Validation data: Examine available western blot images or IHC results to verify the antibody detects a single specific band at the expected molecular weight (21-23 kDa for CSRP1) .

• Citation history: Antibodies with published research citations provide greater confidence in performance reliability .

How can I validate the specificity of a CSRP1 antibody for my research?

To validate CSRP1 antibody specificity:

• Positive and negative controls: Include cell lines known to express CSRP1 (such as ME-180 human cervical epithelial carcinoma cells) as positive controls, and cells with low or no CSRP1 expression (like LNCaP prostate cancer cells) as negative controls .

• Recombinant protein testing: Run purified recombinant CSRP1 alongside related family members (CSRP2, CSRP3) to confirm specificity, as demonstrated in validation studies showing a specific band for CSRP1 at approximately 23 kDa .

• siRNA knockdown: Perform siRNA knockdown of CSRP1 in positive control cells to confirm antibody signal reduction in Western blot or immunostaining.

• Overexpression validation: Compare signal between wild-type cells and those stably expressing CSR1 (such as the PDC1 and PDC4 cell lines referenced) to verify proportional signal intensity .

• Cross-methodology confirmation: Verify consistent results across different detection methods (e.g., Western blot results should align with immunohistochemistry findings) .

What are the optimal conditions for Western blot detection of CSRP1?

For optimal Western blot detection of CSRP1:

• Sample preparation: Prepare cell lysates under reducing conditions using appropriate buffer systems (such as Immunoblot Buffer Group 1 as referenced in protocol) .

• Gel percentage: Use 10-12% SDS-PAGE gels for optimal resolution of the 21-23 kDa CSRP1 protein.

• Membrane selection: PVDF membranes have been successfully used for CSRP1 detection .

• Antibody concentration: For goat anti-human/mouse/rat CSRP1 antibody (catalog #AF5739), a concentration of 0.5 μg/mL has been shown to be effective . For rabbit polyclonal antibodies like #DF3119, optimal dilutions should be determined empirically for each lot .

• Secondary antibody selection: Use species-appropriate HRP-conjugated secondary antibodies (such as anti-goat IgG for AF5739 or anti-rabbit IgG for DF3119) .

• Expected band size: A specific band for CSRP1 should be detected at approximately 21-23 kDa .

• Loading control: Include appropriate loading controls and, when possible, recombinant CSRP1 protein as a positive control .

What protocol modifications are necessary for successful immunohistochemical detection of CSRP1 in different tissue types?

For successful immunohistochemical detection of CSRP1:

• Fixation considerations: Standard formalin fixation and paraffin embedding works well, though optimization of antigen retrieval is critical.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective for CSRP1 detection.

• Blocking parameters: Use 5-10% normal serum (matched to the species of secondary antibody) with 1% BSA in PBS for 1 hour at room temperature.

• Primary antibody incubation: For paraffin sections, incubate with optimized antibody dilution overnight at 4°C; for frozen sections, 1-2 hours at room temperature may be sufficient .

• Signal interpretation: CSRP1 expression is primarily localized to the cytosol and plasma membrane . When scoring staining intensity, consider using a graded system (0-3) as employed in published studies: strong (3), moderate (2), weak (1), focal positive (0.5), or negative (0) .

• Tissue-specific considerations: Prostate tissue may require additional optimization due to variable CSRP1 expression levels between normal and cancerous regions .

How can I establish a stable cell line expressing CSR1/CSRP1 for functional studies?

To establish stable CSR1-expressing cell lines:

• cDNA generation: Generate CSR1 cDNA through RT-PCR using verified primers. Published successful primers include:

  • Sense: 5′-GCATTGCCCTTCTTCTAACGGA-3′

  • Antisense: 5′-ATAGCAGATTGACAGTGACAG-C-3′

• PCR protocol: Use a thermal cycling program of 94°C for 1 minute, 65°C for 1 minute, and 72°C for 2 minutes for 30 cycles .

• Cloning strategy: Purify the PCR product, clone into an intermediate vector for sequence verification, then subclone into an appropriate expression vector (such as pCMV-script) using appropriate restriction enzymes (NotI and KpnI have been successfully used) .

• Transfection method: Transfect target cells (such as PC-3 or DU145 prostate cancer cell lines) using an appropriate method like Superfect reagent .

• Selection: Generate stable expressors using G418 selection at approximately 400 μg/ml .

• Validation: Confirm CSR1 expression by Western blot using validated antibodies .

• Inducible system option: For studies requiring controlled expression, consider constructing an inducible expression system as mentioned in the literature .

What functional assays can best demonstrate the tumor suppressive activity of CSR1/CSRP1?

Based on published research, the following assays effectively demonstrate CSR1's tumor suppressive activity:

• Colony formation assay: CSR1-expressing cell lines show a two- to threefold decrease in colony formation compared to control cells .

• Anchorage-independent growth: Soft agar assays reveal a 10-fold reduction in anchorage-independent growth in CSR1-expressing prostate cancer cells .

• Invasion assay: Transwell matrigel invasion assays demonstrate significant reduction (average threefold decrease) in invasive capability of CSR1-expressing cells .

• Xenograft tumor models: In vivo studies show dramatic reduction (>8-fold) in tumor size when implanting CSR1-expressing PC3 cells compared to control cells .

• Metastasis assessment: Xenograft models can be evaluated for invasion rate (0% versus 31% in control) and mortality differences (13% versus 100% in control) .

• Cell cycle analysis: Flow cytometry to assess cell cycle distribution and potential G1/S checkpoint activation.

• Apoptosis assays: Annexin V staining and caspase activation assays to evaluate potential pro-apoptotic effects.

What approaches can be used to investigate the methylation status of the CSR1 promoter in different cancer types?

To investigate CSR1 promoter methylation:

• Methylation-specific PCR (MSP): Design primers targeting the CpG island in the CSR1 promoter region. Published research has successfully used primers targeting the -193 to -315 region of the CSR1 promoter .

• Primer validation: Validate primer specificity using artificially methylated DNA (via SSSI methylase treatment) followed by bisulfite conversion as a positive control .

• Bisulfite sequencing: For detailed methylation mapping, perform bisulfite conversion followed by sequencing of the CSR1 promoter region.

• Methylation array analysis: Integrate CSR1 methylation status data from genome-wide methylation arrays when available.

• Cell line panel screening: A comprehensive approach can examine methylation across diverse cancer cell lines (prostate, lung, sarcoma, lymphoma, glioblastoma) as demonstrated in published research .

• Correlation with expression: Integrate methylation data with CSR1 expression levels (mRNA and protein) to establish causative relationships .

• Demethylating agent studies: Treat cells with 5-aza-2'-deoxycytidine to determine if CSR1 expression can be restored, confirming methylation as the silencing mechanism.

How does post-translational modification affect CSRP1 function and antibody detection?

Post-translational modifications (PTMs) of CSRP1 can significantly impact both its function and detection:

• Known PTMs: CSRP1 undergoes several post-translational modifications including:

  • Acetylation at K8

  • Ubiquitination at K8 and other lysine residues

• Detection considerations:

  • PTMs may alter antibody epitope accessibility

  • Modified forms may migrate differently during gel electrophoresis

  • Some antibodies may preferentially recognize specific modified or unmodified forms

• Functional implications:

  • PTMs likely regulate CSRP1 protein stability, localization, and protein-protein interactions

  • Ubiquitination may control CSRP1 turnover, affecting its tumor suppressor activity

  • Acetylation could modify CSRP1's interaction with other proteins or DNA

• Experimental approaches:

  • Use phosphatase or deacetylase treatments prior to antibody detection to reveal modification-dependent epitopes

  • Employ PTM-specific antibodies when available

  • Consider IP-mass spectrometry approaches to comprehensively map CSRP1 modifications

What are the current challenges and limitations in designing antibodies with improved specificity for CSRP1?

Current challenges in designing improved CSRP1-specific antibodies include:

Table 1: Comparative Analysis of Commercial CSRP1 Antibodies

Table 2: CSR1 Expression Changes in Prostate Cancer

What are common sources of false positive or negative results when detecting CSRP1, and how can they be mitigated?

Common sources of detection problems and their solutions include:

• False negatives:

  • Insufficient antigen retrieval: Optimize retrieval conditions (buffer pH, duration, temperature)

  • Low CSRP1 expression: Use signal amplification methods or more sensitive detection systems

  • Antibody degradation: Aliquot antibodies and store according to manufacturer recommendations

  • Epitope masking by PTMs: Consider phosphatase or deacetylase treatment of samples

  • Methylation-induced silencing: In cancer samples, CSRP1 may be epigenetically silenced

• False positives:

  • Cross-reactivity with CSRP2/CSRP3: Include recombinant protein controls to verify specificity

  • Non-specific binding: Optimize blocking conditions and antibody dilutions

  • Secondary antibody cross-reactivity: Include secondary-only controls

  • Endogenous peroxidase activity: Ensure adequate quenching in IHC protocols

• Mitigation strategies:

  • Always include positive control samples with known CSRP1 expression (e.g., ME-180 cells)

  • Include negative control samples with low/absent expression (e.g., LNCaP cells)

  • Validate findings using multiple detection methods (WB, IHC, qPCR)

  • Consider using multiple antibodies targeting different CSRP1 epitopes

How can CSR1/CSRP1 expression be accurately quantified in clinical samples for correlation with disease progression?

For accurate quantification of CSRP1 in clinical samples:

• Standardized scoring system: Implement a consistent scoring method for IHC as demonstrated in published work: strong (3 point), moderate (2 point), weak (1 point), focal positive (0.5 point), or negative (0 point) .

• Blinded assessment: Have multiple observers score each sample while blinded to clinical outcomes, then average results as done in published studies .

• Tissue microarray approach: Use tissue microarrays with appropriate controls for high-throughput analysis across multiple samples.

• Multi-method validation: Combine protein detection (IHC) with mRNA analysis (qRT-PCR or RNA-seq) and methylation studies.

• Digital pathology: Employ quantitative image analysis software to obtain objective measures of staining intensity and distribution.

• Statistical correlations: Use appropriate statistical methods to correlate CSRP1 expression levels with clinical parameters such as:

  • Tumor stage and grade

  • Metastasis rate

  • Patient survival

  • Treatment response

• Cut-off determination: Establish clinically relevant expression thresholds through ROC curve analysis and survival correlations.